ORBIMED CAPITAL LLC
Follow13F filer, CIK 1157524, New York, NY
ORBIMED CAPITAL LLC filed a 13F-NT notice for the quarter ended 2026-03-31 on 2026-05-15.
Filed (acceptance time not in the bulk data set), ingested 13F-NT 0001172661-26-002372
This filer reports no holdings of its own for Q1 2026. It filed a 13F-NT notice, and its holdings are in the report of . How notices are handled.
Changes against Q4 2025 are not shown: it was a notice, with the holdings in another manager's report (0 positions on file), so every position would read as new.
Part of the filer group ORBIMED ADVISORS LLC
ORBIMED ADVISORS LLCOrbiMed Advisors Israel II Ltd
- ORBIMED ADVISORS LLC
- OrbiMed Advisors Israel II Ltd
- OrbiMed Advisors IV Limited
- OrbiMed Asia GP IV, L.P.
- OrbiMed Capital GP VIII LLC
- OrbiMed Capital GP VII LLC
- OrbiMed Genesis GP LLC
- OrbiMed Israel GP II, L.P.
Stakes and trades reported after 2026-03-31
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- AVBP ARRIVENT BIOPHARMA INC: 13D/A 2,875,962 shares, 5.8% of the class, 13D/A filed 2026-10-08, 0000947871-26-000931Timeline
Accepted , ingested - ADARX PHARMACEUTICALS INC: 13D 14,913,764 shares, 14% of the class, 13D filed 2026-10-02, 0000947871-26-000917
Accepted , ingested - ELECTRA THERAPEUTICS INC: 13D 6,885,170 shares, 11% of the class, 13D filed 2026-09-25, 0000947871-26-000898
Accepted , ingested
How Q1 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-NT 0001172661-26-002372 | notice | 2026-05-15 | acceptance time not in the bulk data set |